title: Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.
abstract: Cucurbitacins B and D were among the compounds identified as sensitizers of cancer cells to TRAIL-mediated apoptosis in a high-throughput screen. Therefore a series of cucurbitacins was further investigated for TRAIL sensitization and possible mechanisms of action. A total of six cucurbitacins promoted TRAIL-induced apoptosis (B, I, E, C, D, and K) and one (P) was inactive. Sensitization of renal adenocarcinoma cells to TRAIL was apparent after as little as 1-4 h pretreatment and did not require continued presence of cucurbitacin. Active cucurbitacins induced caspase-8 activation only after subsequent TRAIL addition and caspase activation was required for apoptosis suggesting amplified proximal signaling from TRAIL death receptors. Cucurbitacin-sensitized TRAIL-induced cytotoxicity was inhibited by N-acetyl cysteine. Structure-activity relationship analysis in comparison to published studies suggests that TRAIL-sensitizing and general cytotoxic activities of cucurbitacins may be decoupled. Cucurbitacins are reported to be inhibitors of STAT3 activation. However, their TRAIL-sensitizing activity is STAT3-independent. Treatment of renal carcinoma cells with active cucurbitacins produced rapid and dramatic changes in cell morphology and cytoskeletal organization (also prevented by NAC). Therefore, cucurbitacins may be useful as tools for investigating the molecular mechanism(s) of action of TRAIL sensitizers, particularly with regard to temporal aspects of sensitization and modulation of TRAIL signaling by cell morphology, and could form the basis for future therapeutic development in combination with TRAIL death receptor agonists.
authors.affiliation: Molecular Targets Laboratory, NCI-Frederick, Frederick, MD, USA. Curtis.Henrich2@nih.gov
authors.forename: Curtis J
authors.initials: CJ
authors.lastname: Henrich
authors.forename: Cheryl L
authors.initials: CL
authors.lastname: Thomas
authors.forename: Alan D
authors.initials: AD
authors.lastname: Brooks
authors.forename: Nancy Lynn
authors.initials: NL
authors.lastname: Booth
authors.forename: Evan M
authors.initials: EM
authors.lastname: Lowery
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Pompei
authors.forename: James B
authors.initials: JB
authors.lastname: McMahon
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Sayers
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D053181:Caspase 8 / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D048430:Cell Shape / Q000187:drug effects; D054728:Cucurbitacins / Q000494:pharmacology*; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*
chemical_list: D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand; D054728:Cucurbitacins; D053181:Caspase 8